- Report
- August 2022
- 120 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- January 2022
- 90 Pages
North America
From €4273EUR$4,750USD£3,656GBP
- Report
- January 2022
- 90 Pages
Europe
From €4273EUR$4,750USD£3,656GBP
- Report
- January 2022
- 105 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- January 2022
- 115 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- January 2022
- 100 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- January 2022
- 115 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- January 2022
- 114 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- January 2022
- 117 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- July 2021
- 120 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- February 2023
- 118 Pages
From €3104EUR$3,450USD£2,656GBP
- Report
- February 2023
- 111 Pages
North America
From €3104EUR$3,450USD£2,656GBP
- Report
- February 2023
- 107 Pages
Africa, Middle East
From €3104EUR$3,450USD£2,656GBP
- Report
- February 2023
- 126 Pages
Europe
From €3104EUR$3,450USD£2,656GBP
- Report
- February 2023
- 135 Pages
Asia Pacific
From €3104EUR$3,450USD£2,656GBP
- Report
- December 2022
- 190 Pages
Global
From €4003EUR$4,450USD£3,425GBP
- Report
- February 2024
- 115 Pages
Global
From €4273EUR$4,750USD£3,656GBP
- Report
- May 2024
- 130 Pages
Global
From €2843EUR$3,160USD£2,432GBP
€3554EUR$3,950USD£3,041GBP
- Report
- April 2024
- 121 Pages
Global
From €2843EUR$3,160USD£2,432GBP
€3554EUR$3,950USD£3,041GBP
- Report
- April 2024
- 120 Pages
Global
From €3059EUR$3,400USD£2,617GBP
€3823EUR$4,250USD£3,272GBP

The biopharmaceuticals market is a sector of the pharmaceutical industry that focuses on the development and production of drugs derived from biological sources. These drugs are typically produced using recombinant DNA technology, which involves the manipulation of genetic material to create proteins and other molecules with therapeutic properties. Biopharmaceuticals are used to treat a wide range of diseases, including cancer, HIV/AIDS, and autoimmune disorders.
Biopharmaceuticals are typically more expensive to produce than traditional pharmaceuticals, but they offer a number of advantages, such as improved efficacy and fewer side effects. They are also more targeted, meaning they can be used to treat specific conditions more effectively.
Some of the major companies in the biopharmaceuticals market include Amgen, Biogen, Celgene, Gilead Sciences, and Novartis. These companies are involved in the development and production of a wide range of biopharmaceuticals, including monoclonal antibodies, vaccines, and gene therapies. Show Less Read more